Sphingosine-1-phosphate controls endothelial sphingolipid homeostasis via ORMDL

Sphingolipid imbalances are linked to diabetes, cancer, and neurodegenerative diseases. Despite this, the mechanisms by which cells sense and regulate sphingolipid levels remain unclear. In yeast, Orm1 and Orm2 proteins regulate serine palmitoyltransferase, a key enzyme in sphingolipid biosynthesis. Phosphorylation of Orm proteins occurs when sphingolipid levels drop, which activates biosynthesis. Mammalian ORMDL proteins lack the phosphorylation sites found in yeast Orms, leaving the identity of the sensed sphingolipid and the regulatory mechanism unknown. Prior research has shown that sphingolipid disruption affects multiple physiological systems, but the specific sensing mechanisms have not been established. This gap motivated researchers to investigate whether sphingosine-1-phosphate (S1P) might serve as a signaling molecule in mammalian cells. No prior work had resolved the role of S1P in ORMDL regulation. The lack of clarity on how mammalian cells maintain sphingolipid balance limits understanding of related diseases. This uncertainty drove the current investigation into S1P’s role in homeostasis.

The study aimed to identify the sphingolipid that mammalian cells use to sense and regulate sphingolipid homeostasis. Researchers focused on S1P as a potential signaling molecule due to its known roles in cell signaling. The specific problem addressed was the lack of understanding about which sphingolipid interacts with ORMDL proteins to control biosynthesis. The motivation was to uncover the molecular mechanism linking S1P to ORMDL function and sphingolipid regulation. The study also sought to determine how S1P signaling affects ORMDL stability and SPT activity. By examining the role of S1P and ORMDLs, the researchers aimed to clarify the regulatory pathway. They hypothesized that S1P might stabilize ORMDLs, thereby inhibiting SPT activity. The study’s goal was to provide a mechanistic framework for sphingolipid homeostasis in mammalian cells.

The researchers used a combination of biochemical assays and cell culture techniques to investigate S1P’s role. They first measured S1P levels in cells under various conditions to assess its regulatory function. Next, they examined ORMDL protein stability in response to S1P-S1PR signaling. Using proteasome inhibitors, they tested whether ORMDL degradation occurs via the ubiquitin-proteasome pathway. The team also employed site-directed mutagenesis to study the role of Pro137 in ORMDL hydroxylation. They analyzed SPT activity in cells with altered ORMDL levels to determine its impact on sphingolipid biosynthesis. Additionally, they assessed mitochondrial function and ceramide levels in cells with disrupted S1PR/ORMDL signaling. The study combined molecular biology techniques with functional assays to establish a causal relationship between S1P and ORMDL regulation.

The strongest finding was that S1P acts as a key sphingolipid sensed by cells via S1PRs to maintain homeostasis. Increased S1P-S1PR signaling stabilizes ORMDL proteins, which in turn inhibits serine palmitoyltransferase (SPT) activity. Mechanistically, hydroxylation of ORMDL at Pro137 enables constitutive degradation via the ubiquitin-proteasome pathway. Disrupting the S1PR/ORMDL axis leads to ceramide accumulation and mitochondrial dysfunction. These effects impair signal transduction and contribute to endothelial dysfunction. The study found that ORMDL stabilization correlates with reduced SPT activity. Ceramide levels increased significantly when S1P signaling was blocked. Mitochondrial dysfunction was observed in cells lacking functional S1PR/ORMDL signaling. The results suggest a direct link between S1P signaling and endothelial health.

The authors propose that S1P functions as a critical sensor of sphingolipid homeostasis via S1PRs and ORMDLs. Their findings suggest that S1P signaling stabilizes ORMDL proteins, which in turn inhibits SPT activity. The hydroxylation of ORMDL at Pro137 allows for its degradation, preserving SPT activity. Disrupting the S1PR/ORMDL axis leads to ceramide accumulation and mitochondrial dysfunction. These effects may underlie endothelial dysfunction observed in cardio- and cerebrovascular diseases. The study supports the idea that S1P and ORMDLs work together to regulate sphingolipid levels. The authors suggest that this regulatory mechanism may serve as a molecular basis for therapeutic interventions. Their findings do not establish essentiality but propose a potential pathway for restoring sphingolipid homeostasis.